| Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia (NCT07564453) | The First Affiliated Hospital of Soochow University | 2025-04-01 |
| Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism (NCT06858254) | Apeiron Research Center | 2025-04-01 |
| Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial (NCT06771154) | Peking Union Medical College Hospital | 2025-04-01 |
| Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis (NCT06896253) | Assistance Publique - Hôpitaux de Paris | 2025-04-01 |
| Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease (NCT05685368) | Children's Hospital Los Angeles | 2025-04-01 |
| Blinatumomab for Treatment of Refractory Myasthenia Gravis (NCT06836973) | Da, Yuwei, M.D. | 2025-04-01 |
| Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction (NCT05766514) | University of Florida | 2025-04-01 |
| Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial (NCT07020754) | Ain Shams University | 2025-04-01 |
| Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder (NCT06951854) | Neuroventi Inc. | 2025-04-01 |
| Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC (NCT06939127) | Tianjin Medical University Cancer Institute and Hospital | 2025-04-01 |
| Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients (NCT06897605) | Mansoura University | 2025-04-01 |
| Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma (NCT06940700) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2025-04-01 |
| Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction (NCT06634030) | Vanderbilt University Medical Center | 2025-04-01 |
| Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery (NCT06678399) | Kelifarma | 2025-04-01 |
| Alginate vs Sucralfate for GERD Symptomatic Relief (NCT07310927) | CMH Lahore Medical College and Institute of Dentistry | 2025-04-01 |
| Virtual Reality for Cognitive Impairment in Hemodialysis (NCT06739187) | University of Campania Luigi Vanvitelli | 2025-04-01 |
| Non Steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy (NCT06903585) | American University of Beirut Medical Center | 2025-04-01 |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity (NCT06862908) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-04-01 |
| Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT07363486) | First Affiliated Hospital of Fujian Medical University | 2025-04-01 |
| A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors (NCT06906731) | Jiangsu HengRui Medicine Co., Ltd. | 2025-04-01 |
| HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer (NCT06849492) | Fudan University | 2025-04-01 |
| Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes (NCT06951074) | Ain Shams University | 2025-04-01 |
| Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety (NCT06894836) | Orygen | 2025-04-01 |
| Efgartigimod for Stiff Person Syndrome (ESPS) (NCT06528392) | University of South Florida | 2025-04-01 |
| Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes (NCT06854861) | St. Olavs Hospital | 2025-04-01 |
| Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations (NCT07012447) | yuejun Liu | 2025-04-01 |
| Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients (NCT06901999) | Ruijin Hospital | 2025-04-01 |
| Community-based Behavioral Intervention to Increase Vaccination Using MOST (NCT06614361) | New York University | 2025-04-01 |
| To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study (NCT06918743) | Jiangsu HengRui Medicine Co., Ltd. | 2025-04-01 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy (NCT05936229) | Fred Hutchinson Cancer Center | 2025-04-01 |
| Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL (NCT07448324) | The First Affiliated Hospital with Nanjing Medical University | 2025-04-01 |
| A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) (NCT06864169) | Merck Sharp & Dohme LLC | 2025-04-01 |
| Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL (NCT07058103) | The Affiliated Hospital of Xuzhou Medical University | 2025-04-01 |
| Opioid Drug Interaction Study (NCT06757140) | Shanna Babalonis, PhD | 2025-04-01 |
| A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases (NCT05669352) | University of Florida | 2025-04-01 |
| Optimal Dose of Antivenom for Daboia Siamensis Envenomings (NCT04210141) | Myanmar Oxford Clinical Research Unit | 2025-04-01 |
| Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke (NCT06900725) | National Taiwan University Hospital | 2025-04-01 |
| A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer (NCT06919510) | Sun Yat-sen University | 2025-04-01 |
| Assessment of Noninvasive Neuromodulation in a Group of Traumatic Brain Injured Patients and Healthy Volunteers (NCT07373366) | University of Sao Paulo | 2025-04-01 |
| Oral Melatonin VS Nebulized Dexmedetomidine Premedication on Attenuation of Hemodynamic Response to Direct Laryngoscopy and Tracheal Intubation in Hypertensive Patients (NCT06935292) | Tanta University | 2025-04-01 |
| Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer. (NCT06888648) | Zhejiang University | 2025-04-01 |
| Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) (NCT06518720) | Centre for Addiction and Mental Health | 2025-04-01 |
| Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (NCT06895031) | Guangzhou JOYO Pharma Co., Ltd | 2025-03-31 |
| Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) (NCT06923345) | Sixth Affiliated Hospital, Sun Yat-sen University | 2025-03-31 |
| A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) (NCT06943833) | AstraZeneca | 2025-03-31 |
| Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. (NCT06885840) | Betta Pharmaceuticals Co., Ltd. | 2025-03-31 |
| The Effect and Safety of Anti-inflammatories and Dextrose Prolotherapy Injections in Treating Knee Osteoarthritis (NCT06911359) | David Grant U.S. Air Force Medical Center | 2025-03-31 |
| Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer (NCT06665178) | British Columbia Cancer Agency | 2025-03-31 |
| A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis (NCT06693908) | Genentech, Inc. | 2025-03-31 |
| Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH) (NCT06922994) | Centro Cardiologico Monzino | 2025-03-31 |
| Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer (NCT06470282) | University of California, San Francisco | 2025-03-31 |
| Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer (NCT06908668) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-03-31 |
| A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma (NCT06869213) | Peking University Cancer Hospital & Institute | 2025-03-31 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria. (NCT06864507) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-03-31 |
| The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) (NCT06921486) | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 2025-03-31 |
| CMTS4520 for Chronic Constipation in Adults (NCT06832137) | The Second Hospital of Nanjing Medical University | 2025-03-31 |
| Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (NCT06692907) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-03-31 |
| Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer (NCT06888037) | Ruijin Hospital | 2025-03-31 |
| A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease (NCT06807463) | Teva Branded Pharmaceutical Products R&D LLC | 2025-03-31 |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. (NCT06898450) | Nimbus Wadjet, Inc. | 2025-03-31 |
| Acupuncture for People Experiencing Period Loss Due to Chemotherapy (NCT06915116) | Memorial Sloan Kettering Cancer Center | 2025-03-31 |
| Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC (NCT06908733) | Liaoning Cancer Hospital & Institute | 2025-03-31 |
| Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma (NCT06838910) | The First Affiliated Hospital with Nanjing Medical University | 2025-03-31 |
| Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease (NCT06925061) | Madeleine Bezault | 2025-03-31 |
| Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC (NCT06688656) | Shanghai Chest Hospital | 2025-03-31 |
| A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma (NCT06891560) | Memorial Sloan Kettering Cancer Center | 2025-03-31 |
| A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound (NCT07304024) | University of Colorado, Denver | 2025-03-31 |
| Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy (NCT06868836) | Shanghai Junshi Bioscience Co., Ltd. | 2025-03-30 |
| Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC (NCT06900478) | Hua Li | 2025-03-30 |
| A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) (NCT06731907) | Merck Sharp & Dohme LLC | 2025-03-30 |
| QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer (NCT07205497) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2025-03-28 |
| A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors (NCT07744763) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-03-28 |
| A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 (NCT06900816) | Chiesi Farmaceutici S.p.A. | 2025-03-28 |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL (NCT06854653) | Prescient Therapeutics, Ltd. | 2025-03-28 |
| A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer (NCT06944106) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-28 |
| A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis (NCT06875934) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2025-03-28 |
| Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin (NCT06731933) | Stanford University | 2025-03-28 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis (NCT06867094) | Sanofi | 2025-03-28 |
| Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults (NCT06869187) | Autobahn Therapeutics, Inc. | 2025-03-28 |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (NCT06421675) | Ontario Clinical Oncology Group (OCOG) | 2025-03-28 |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide (NCT06897475) | Eli Lilly and Company | 2025-03-28 |
| Myofascial Dysfunction in Post Stroke Shoulder Pain (NCT06718413) | Johns Hopkins University | 2025-03-28 |
| A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (NCT06895928) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-03-28 |
| Reusable Face Masks to Reduce Risk of Viral Respiratory Infections and Asthma Exacerbations (NCT06885229) | Queen Mary University of London | 2025-03-27 |
| Zhibitai Capsules for the Treatment of Primary Hyperlipidemia (NCT06822946) | Chengdu Diao Jiuhong Pharmaceutical Factory | 2025-03-27 |
| Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells (NCT06653777) | UNICANCER | 2025-03-27 |
| A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer. (NCT06844357) | Zhejiang Raygene Pharmaceuticals Co., Ltd | 2025-03-27 |
| Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) (NCT07264647) | Fondazione Ricerca Traslazionale | 2025-03-27 |
| Study of Yupingfeng Powder Treating Allergic Rhinitis (AR) (NCT06608017) | Chinese University of Hong Kong | 2025-03-27 |
| Mediterranean Diet and Inequality in Early Breast Cancer (NCT07007169) | Esbjerg Hospital - University Hospital of Southern Denmark | 2025-03-27 |
| Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy (NCT06421532) | Leiden University Medical Center | 2025-03-27 |
| Comparison of the Effectiveness of Classical Perineal Massage Therapy Versus the Use of an Intravaginal Device to Reduce Postpartum Perineal Pain (NCT06921174) | Instituto Sexológico Murciano | 2025-03-27 |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours (NCT06795022) | AstraZeneca | 2025-03-27 |
| Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years (NCT06891417) | Sanofi | 2025-03-27 |
| Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024) (NCT06997367) | Bharat Biotech International Limited | 2025-03-27 |
| A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours (NCT06873854) | LaNova Medicines Limited | 2025-03-26 |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (NCT06932263) | AstraZeneca | 2025-03-26 |
| A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients (NCT06857955) | Novartis Pharmaceuticals | 2025-03-26 |
| Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors (NCT06635785) | OncoC4, Inc. | 2025-03-26 |
| Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma (NCT06831136) | The University of Texas Health Science Center, Houston | 2025-03-26 |